Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BlueRock Therapeutics

- PMLiVE

AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies

Biotech company did not disclose the reason for the partnership's end

- PMLiVE

Merck, Bayer get FDA priority review for heart failure drug

Target action date set for January 2021

Impetus Digital Fireside Chat with Tom Hsu, VP, Specialty Medicine at Bayer Canada

Tom Hsu, VP of Specialty Medicine at Bayer Canada,  talks about how he got to where he is today and his experience working for Bayer in China, and how that compares to...

Impetus Digital

Bayer symbol

Bayer gets EU nod for prostate cancer drug Nubeqa

Enters an increasingly competitive market

- PMLiVE

Merck, Bayer flesh out vericiguat heart failure data at ACC

Drug reduced rate of cardiovascular deaths and hospitalisations

- PMLiVE

Lundbeck drops Parkinson’s drug acquired in €905m deal

Disappointment after drug failed in a mid-stage clinical trial

Bayer symbol

Bayer signs €250m pact with India’s Curadev for STING drugs

Research will focus on auto-immune and inflammatory diseases

- PMLiVE

Biogen bulks up in Alzheimer’s again with $2.7bn Sangamo deal

Gains rights to tau-targeting drug ST-501 as part of broader alliance

- PMLiVE

Servier and Oncodesign reach first milestone in Parkinson’s partnership

Oncodesign receives first success payment of €1m

Novartis day

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

New drug due for launch in Europe in the second quarter

Bayer symbol

Bayer bulks up in women’s health again with non-hormonal contraceptive deal

If approved candidate would become a first-in-category therapy

Bayer symbol

Bayer extends alliance with Evotec in women’s health

Five-year research agreement focuses on polycystic ovary syndrome

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links